Victory Capital Management
AERI

Victory Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Victory Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,028
Closed -$176K – 3535
2020
Q1 		$176K Buy
13,028
+4,658
+56% +$88.4K ﹤0.01% 2366
2019
Q4 		$202K Buy
8,370
+1,259
+18% +$26.1K ﹤0.01% 2313
2019
Q3 		$137K Buy
+7,111
New +$163K ﹤0.01% 2337

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Victory Capital Management's AERI Position: Q2 2020 in Review

Victory Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 13,028 shares — an estimated $176K sold.

Victory Capital Management first reported a position in AERI in Q3 2019 and held it in 3 quarters. The position peaked at $202K in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

  • Victory Capital Management reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 13,028 Aerie Pharmaceuticals shares in Q2 2020, an estimated $176K.
  • Victory Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Victory Capital Management's Aerie Pharmaceuticals position peaked at $202K in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.